|
|
||||||||
Department of Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| |
ABSTRACT |
|---|
|
|
|---|
To investigate the possible involvement of histamine
H3 receptors in renal noradrenergic neurotransmission,
effects of (R)alpha-methylhistamine (R-HA), a selective
H3-receptor agonist, and thioperamide (Thiop), a selective
H3-receptor antagonist, on renal nerve stimulation (RNS)-induced changes in renal function and norepinephrine (NE) overflow in anesthetized dogs were examined. RNS (0.5-2.0 Hz) produced significant decreases in urine flow and urinary sodium excretion and increases in NE overflow rate (NEOR), without affecting renal hemodynamics. When R-HA (1 µg · kg
1 · min
1) was
infused intravenously, mean arterial pressure and heart rate were
significantly decreased, and there was a tendency to reduce basal
values of urine flow and urinary sodium excretion. During R-HA
infusion, RNS-induced antidiuretic action and increases in NEOR were
markedly attenuated. Thiop infusion (5 µg · kg
1 · min
1) did not
affect basal hemodynamic and excretory parameters. Thiop infusion
caused RNS-induced antidiuretic action and increases in NEOR similar to
the basal condition. When R-HA was administered concomitantly
with Thiop infusion, R-HA failed to attenuate the RNS-induced
antidiuretic action and increases in NEOR. However, in the presence of
pyrilamine (a selective H1-receptor antagonist) or
cimetidine (a selective H2-receptor antagonist) infusion,
R-HA attenuated the RNS-induced actions, similarly to the case without these antagonists. Thus functional histamine H3 receptors,
possibly located on renal noradrenergic nerve endings, may play the
role of inhibitory modulators of renal noradrenergic neurotransmission.
renal nerve stimulation; norepinephrine overflow
| |
INTRODUCTION |
|---|
|
|
|---|
HISTAMINE H3 receptors were discovered to be presynaptic autoreceptors present on histaminergic nerve endings. Stimulation of H3 receptors inhibits release and synthesis of histamine (2, 3). Histamine H3 receptors are also involved in regulating the release of neurotransmitters, such as acetylcholine, dopamine, norepinephrine (NE), and 5-hydroxytryptamine, in both central and peripheral nervous systems (5, 16, 17, 27, 29).
Effects on cardiac functions of (R)alpha-methylhistamine (R-HA), a selective agonist of H3 receptor, have been reported. McLeod at al. (24) found that R-HA decreased blood pressure with ensuing tachycardiac and bradycardiac effects in anesthetized guinea pigs and conscious rabbits, respectively, hence indicating a species difference in cardiovascular responses. R-HA attenuates inotropic and chronotropic responses of isolated guinea pig atria to transmural stimulation of adrenergic nerve endings (8). In addition, this attenuation is associated with a marked decrease in endogenous NE release (8). Similar inhibitory effects of R-HA on NE release have been observed in sympathetic nerve endings isolated from human atria (16). Mazenot et al. (23) reported that R-HA inhibits NE release and related hemodynamic effects induced by the electrical stimulation of cardiac nerve endings in anesthetized dogs. These findings strongly suggest the important role of presynaptic H3 receptors as inhibitory modulators of cardiac noradrenergic neurotransmission.
The functional role of H3 receptors in the kidney has remained obscure. Renal sympathetic nerve activity is closely involved in regulatory mechanisms of renal hemodynamics and excretory responses. NE released from nerve endings leads to renal vasoconstriction and an increased tubular reabsorption to diminish renal hemodynamics, urine flow (UF), and urinary excretion of sodium (UNaV), respectively (21, 22, 32). We investigated if activation of H3 receptors in the kidney would modulate the release of NE from the sympathetic nerve endings, and for this we examined effects of R-HA and thioperamide (Thiop), a selective H3-receptor antagonist, on renal nerve stimulation (RNS)-induced renal actions and NE overflow in anesthetized dogs. We now report here the first evidence for functional H3 receptors as inhibitory modulators of renal noradrenergic neurotransmission in dogs.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animal preparation. Adult male beagle dogs weighing 9.5-13.5 kg were used. These dogs were anesthetized with pentobarbital sodium (30 mg/kg iv) and were given maintenance doses as needed. These dogs were placed on a heated surgical table that maintained the rectal temperature between 37 and 38°C. After tracheal intubation of the animals, respiration was supported by artificial ventilation with room air, using a Harvard respirator. Polyethylene catheters were placed in the right brachial artery and vein for arterial blood sampling and for infusion of saline or drug solution containing 0.45% inulin, respectively. Mean arterial blood pressure (MAP) and heart rate (HR) were monitored using a pressure transducer (Nihon Kohden, AP601G, Tokyo, Japan) connected to a polyethylene catheter placed in the abdominal aorta via the right femoral artery. The left kidney was exposed retroperitoneally through a flank incision, and the renal artery was isolated from surrounding tissues. All visible nerve fibers along the renal artery were isolated, ligated, and cut. For RNS, the distal cut portion was placed on bipolar platinum electrodes connected to an electric stimulator (Nihon Kohden, SEN-7103). An electromagnetic flow probe (2.0-3.5 mm in diameter) connected to a square-wave flowmeter (Nihon Kohden, MFV-2100) was attached around the left renal artery to continuously measure renal blood flow (RBF). A curved 18-gauge needle connected to polyethylene tubing was inserted into the left renal vein for venous blood sampling. The left ureter was then cannulated for urine collection. After completing the surgical procedures, a priming dose of inulin (20 mg/kg) was given, followed by infusion of 0.9% saline containing 0.45% inulin for purposes of measuring the glomerular filtration rate (GFR), at a rate of 2.0 ml/min. The MAP, HR, and RBF were continuously recorded on a polygraph (Nihon Kohden, RM6000G). About 2 h were allowed for stabilization.
Experimental protocol (experiment 1: effects of R-HA on RNS-induced renal actions). Two RNS experiments were done on each of seven dogs. Each experiment consisted of a 10-min control period and a 10-min RNS period. Blood samples (3.0 ml) were taken at 5 min in the control period and at 1 and 9 min in the RNS period from the right brachial artery and left renal vein, respectively. After the systemic arterial hematocrit was measured by the microcapillary method, plasma was immediately separated by centrifugation. Urine samples were collected during the latter 5 min in each period. Hemodynamic parameters such as MAP, HR, and RBF were determined at the midpoint of each period.
During the first RNS experiment (0.5-2.0 Hz, duration 1.0 ms, and supramaximal voltage 10-25 V), saline was infused. About 30 min after the first RNS experiment was terminated, intravenous infusion of R-HA (1 µg · kg
1 · min
1)
was started. After 30 min, the second RNS experiment was done under
conditions of drug infusion in the same manner as the first experiment.
In this study, RNS was done at a low frequency that has no influence on
systemic and renal hemodynamics (12).
Experimental protocol (experiment 2: effects of R-HA on
RNS-induced renal actions in the presence of Thiop).
Three RNS experiments were done in six dogs. After equilibration,
the first RNS experiment was done during saline infusion, in the
same manner as for experiment 1. About 30 min after the first experiment was terminated, the intravenous infusion of Thiop (5 µg · kg
1 · min
1) was
started. After 30 min, the second RNS experiment was done in the
presence of Thiop. The third experiment was done during the
simultaneous infusion of R-HA (1 µg · kg
1 · min
1) with
Thiop (5 µg · kg
1 · min
1). The
dose of Thiop was determined based on inhibitory effects of Thiop on
R-HA-induced changes in systemic hemodynamics. In separate experiments,
pyrilamine (5 µg · kg
1 · min
1, a
selective H1- receptor antagonist) (13) or
cimetidine (100 µg · kg
1 · min
1, a
selective H2-receptor antagonist) (13) was
used instead of Thiop.
Analytic procedures.
GFR was estimated as based on inulin clearance. The urine and plasma
inulin levels were measured spectrofluorometrically (Hitachi, 650-60, Hitachinaka, Japan) according to Vurek and Pegram
(33). Urine and plasma sodium concentrations were
determined using a flame photometer (Hitachi, 205D). The plasma NE
concentration was measured using high performance liquid chromatography
and an amperometric detector (ECD-100, Eicom, Kyoto, Japan),
as reported (12). The NE overflow rate (NEOR)
was calculated by NEOR
(pg · g
1 · min
1) = (NEV-NEA)RPF, where RPF is the renal plasma
flow (µl · kg
1 · min
1),
NEV is the renal venous plasma NE concentration (pg/ml),
and NEA is the renal arterial plasma NE concentration
(pg/ml). NEOR served for measurement of renal NE spillover, which
reflects the renal sympathetic nervous activity (9).
Drugs. R-HA and Thiop were purchased from Sigma Chemical (St. Louis, MO), and all other chemicals were obtained from Nacalai Tesque (Kyoto, Japan) and Wako Pure Chemical Industries (Osaka, Japan).
Statistical analysis. All data are expressed as means ± SE. For statistical analyses, we used paired or unpaired Student's t-test for two-sample comparisons. When comparing normalized data in three groups, we used Kruskal-Wallis nonparametric ANOVA test followed by Dunn's multiple comparison test. For all comparisons, differences were considered to have statistical significance at P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Effects of R-HA on RNS-induced renal actions (experiment 1).
RNS at 0.5-2.0 Hz decreased UF, UNaV, and fractional excretion of
sodium (FENa) by ~64, 65, and 62% from each control values of 22.4 µg · g
1 · min
1, 4.49 µeq · g
1 · min
1, and
3.41%, respectively, without affecting systemic and renal hemodynamics
(Fig. 1, Table
1). When R-HA (1 µg · kg
1 · min
1) was
intravenously infused, basal values of MAP and HR were significantly decreased (Table 1). In addition, there was a tendency to reduce basal
values of UF, UNaV, and FENa, although observed changes were not
statistically significant (Fig. 1). During R-HA infusion, RNS-induced
decreases in UF, UNaV, and FENa were significantly attenuated, and
observed changes were
37,
30, and
31%, respectively (Fig. 1). No
significant changes in systemic and renal hemodynamics were observed in
RNS during the R-HA infusion (Table 1).
|
|
Effects of R-HA on RNS-induced increase in NEOR (experiment 1).
RNS during saline infusion significantly increased NEOR from a
control value of
573.6 ± 165.4 to 155.1 ± 275.7 and
148.8 ± 259.3 pg · g
1 · min
1 at 1 and 9 min after the start of RNS, respectively. In the following results,
RNS-induced increases in NEOR from control are indicated as
NEOR to
clarify changes in NEOR induced by the RNS. The intravenous infusion of
R-HA significantly attenuated increases in
NEOR during RNS (from
728.7 ± 178.1 and 722.4 ± 194.6 to 152.0 ± 28.4 and 315.7 ± 61.2 pg · g
1 · min
1 at 1 and 9 min after the start of RNS, respectively; Fig.
2).
|
Effects of R-HA on RNS-induced renal actions in the presence of
Thiop (experiment 2).
Intravenous infusion of Thiop (5 µg · g
1 · min
1) had no
apparent effect on basal systemic and renal hemodynamics, and excretory responses (Table 2, Fig.
3). RNS produced no significant
effects on systemic and renal hemodynamics in the presence or absence of Thiop (Table 2). The RNS-induced attenuation of excretory responses
during saline infusion (UF, UNaV, and FENa decreased by ~49, 41, and
41% from control values of 34.6 ± 5.1 µl · g
1 · min
1, 7.00 ± 1.00 µeq · g
1 · min
1,
and 5.79 ± 0.68%, respectively) was not significantly changed by
Thiop (Fig. 3). When R-HA was administered in the presence of Thiop
infusion, R-HA-induced decreasing actions on MAP, HR, RBF, and UF were
not observed (Table 2, Fig. 3). During the simultaneous infusion of
R-HA and Thiop, systemic and renal hemodynamics were not significantly
changed by RNS (Table 2). As shown in Fig. 3, when R-HA was
administered in the presence of Thiop infusion, R-HA failed to
attenuate the RNS-induced antidiuretic and antinatriuretic actions.
|
|
Effects of R-HA on RNS-induced increase in NEOR in the presence of
Thiop (experiment 2).
As shown in Fig. 4, RNS-induced increases
in
NEOR during saline infusion were not affected by Thiop infusion.
In addition, when R-HA was infused simultaneously with Thiop, the
RNS-induced increases in
NEOR were similar to those observed with
saline infusion (Fig. 4).
|
Effects of R-HA on RNS-induced renal actions and increase in NEOR
in the presence of pyrilamine or cimetidine (experiment 2).
To verify the receptor specificity of R-HA-induced inhibitory effects
on renal actions and NE overflow in response to the RNS, effects of
R-HA were examined in the absence or presence of pyrilamine (a
selective H1-receptor antagonist) or cimetidine (a
selective H2-receptor antagonist). Intravenous infusion of pyrilamine (5 µg · kg
1 · min
1) had no
apparent effect on basal systemic and renal hemodynamics or excretory
responses. During pyrilamine infusion, the RNS-induced decreases in UF,
UNaV, and FENa (~57, 54, and 55%, respectively) and increases in
NEOR (652.6 ± 96.3 and 685.4 ± 103.1 pg · g
1 · min
1 at 1 and 9 min after the start of RNS, respectively) were observed to an extent
similar to those seen without the drug infusion. When R-HA was
administered in the presence of pyrilamine infusion, R-HA-induced
decreasing actions on basal levels of MAP, HR, RBF, and UF were
observed similarly to the case in experiment 1. In the
presence of pyrilamine, R-HA significantly attenuated the RNS-induced
decreases in UF, UNaV, and FENa, and observed changes were
30,
27,
and
28%, respectively. Similarly, R-HA markedly attenuated the
increased responses of
NEOR to the RNS (108.9 ± 24.3 and
215.8 ± 48.3 pg · g
1 · min
1 at 1 and 9 min after the start of RNS, respectively). When we used cimetidine (100 µg · kg
1 · min
1) instead
of pyrilamine, qualitatively similar results were obtained (data not shown).
Assessment of reproducibility of repeated RNS-induced renal actions. Changes in renal hemodynamics, urinary parameters, and NEOR in response to repeated RNS during saline infusion were evaluated. The RNS-induced renal actions were reproducible throughout three repeated RNS experiments (data not shown).
| |
DISCUSSION |
|---|
|
|
|---|
In the present study, RNS at a low frequency (0.5-2.0 Hz) led
to decreases in UF and urinary sodium excretion without affecting systemic and renal hemodynamics. Intravenous infusion of R-HA (1 µg · kg
1 · min
1)
attenuated renal excretory responses to RNS, but this attenuating effect was not observed during the simultaneous administration of
Thiop. To clarify mechanisms underlying these renal responses, we
examined NEOR during RNS, with or without drug infusion. Intravenous administration of R-HA markedly attenuated NE overflow induced by RNS,
but this attenuation was not observed during the simultaneous administration of Thiop. On the other hand, in the presence of pyrilamine or cimetidine, R-HA could attenuate the RNS-induced actions
to an extent similar to the case without these antagonists. Taken
together, it is likely that R-HA inhibited the RNS-induced renal action
and NE overflow by stimulating H3 receptors that probably
function as inhibitory modulators of renal noradrenergic neurotransmission at prejunctional sites.
The human H3 receptor was recently cloned (19). The H3 receptor-signaling pathway involves pertussis toxin-sensitive Gi/Go protein and a decrease in calcium influx through N-type calcium channels (8, 13). Activation of prejunctional H3 receptors reduces NE release and/or sympathetic activity in the heart. Imamura et al. (16) and Mazenot et al. (23) reported that H3-receptor activation by R-HA reduces NE overflow in response to electrical nerve stimulation in isolated human atria and in anesthetized dogs, respectively. R-HA also attenuates inotropic and chronotropic responses as well as endogenous NE release in isolated guinea pig atria in the case of transmural stimulation of adrenergic nerve endings (8). In addition, prejunctional H3 receptors in other tissues, including brain (1, 26), spinal cord (4), and blood vessels (10, 17, 25), also appear to regulate noradrenergic neurotransmission by inhibiting NE release.
In the present study, intravenous administration of R-HA led to hypotensive and bradycardiac effects, events abolished by the simultaneous infusion of Thiop, thereby suggesting that R-HA-induced actions are mediated by the activation of H3-receptor subtype. These results are in agreement with findings by McLeod et al. (24), who noted that R-HA-induced hypotensive and bradycardiac effects in guinea pigs were blocked by Thiop but not by H1 antagonist chlorpheniramine or H2 antagonist cimetidine. On the other hand, Thiop alone had no apparent effects on basal systemic hemodynamics. There are conflicting findings with respect to the cardiovascular effects of H3 antagonists. In guinea pigs, rabbits, and rats, H3 antagonists failed to induce significant cardiovascular effects (6, 24). In contrast, Mazenot et al. (23) noted vasopressor and tachycardiac effects in dogs in response to treatment with the H3 antagonist SC-359, and they suggested that H3 receptors are tonically functional and activated by endogenous histamine to regulate the cardiac function. The reason for these discrepancies is unclear, but there may be species differences (and/or differences in experimental conditions) in cardiovascular responses to H3-receptor activation and inhibition, as suggested by MacLeod et al. (24).
There are reports indicating that a pathological condition leads to an increase in endogenous histamine levels and activation of H3 receptors (11, 15). Imamura et al. (15) noted that in isolated guinea pig hearts exposed to ischemia-reperfusion, H3 receptors were fully activated by increased endogenous histamine to suppress NE overflow from sympathetic nerves; therefore, Thiop markedly potentiated the ischemia-reperfusion-induced NE release, in contrast to the finding that Thiop had no effects on sympathetic nerve stimulation-induced NE overflow under physiological conditions. Thus, although there is information on the physiological and pathological roles of H3 receptors in the heart, the functional roles of this receptor in the kidney have remained an open question. In our study, R-HA inhibited RNS-induced changes in renal function and NE overflow, and this attenuating effect of R-HA was antagonized by the selective H3-receptor antagonist Thiop. However, basal renal function and RNS-induced renal actions were not affected by blockade of the H3 receptor. We suggest that in the dog kidney under physiological conditions, histamine H3 receptors are present and available for exogenously applied ligand to negatively modulate NE release, whereas endogenous histamine does not tonically activate H3 receptor, as seen in the guinea pig heart (15). Whether endogenous histamine levels, under renal pathological conditions, are sufficiently elevated to activate H3 receptors remains the subject of further study.
It is well acknowledged that NE release from sympathetic nerve endings
is modulated by a presynaptic
2-adrenoceptor-mediated inhibitory mechanism. In the same experimental system using
anesthetized dogs, intrarenal administration of yohimbine potentiated
the RNS-induced renal vasoconstriction and NE overflow, thereby
indicating that the presynaptic
2-adrenoceptor-mediated
inhibitory mechanism exists in the dog kidney, which can be activated
by endogenously released NE (14). In our study,
RNS-induced renal actions and NE overflow were not enhanced by the
administration of Thiop, thus suggesting that Thiop does not affect the
presynaptic
2-adrenoceptor-mediated inhibitory mechanism.
By way of summary, histamine H3-receptor activation by R-HA attenuated the RNS-induced antidiuretic action and NE overflow in anesthetized dogs, events abolished by treatment with Thiop, a selective H3-receptor antagonist. We propose an important role for this receptor subtype as an inhibitory modulator of renal noradrenergic neurotransmission at the prejunctional level.
Perspectives
In various organs and vascular tissues, neurotransmitter release from sympathetic nerve endings is modulated by released NE itself and by various humoral factors through stimulation of their receptors located at presynaptic sites. Also, in the kidney there are facilitatory
2-adrenergic and inhibitory
2-adrenergic receptors. In addition, humoral factors
such as angiotensin II, prostaglandin E2, nitric oxide, and
endothelin-1 have been demonstrated to function as a facilitatory or an
inhibitory modulator of renal noradrenergic neurotransmission via
prejunctional mechanisms, although the precise mechanism, including
signaling pathways, remains to be elucidated (7, 20, 30,
31). In the present study, we reported the first evidence for
functional histamine H3 receptor as an inhibitory modulator
of renal noradrenergic neurotransmission in dogs. Because H3-receptor antagonist alone failed to enhance the
RNS-induced NE overflow, physiological level of endogenous histamine
does not seem to inhibit tonically the release of NE in the kidney. On
the other hand, there is a possibility that the H3
receptor-mediated action to negatively modulate NE release at renal
sympathetic nerve endings may play an important role, if an endogenous
histamine level is elevated under some pathological conditions. In the
ischemic heart, histamine H3 receptors appear to be
fully activated by an increased endogenous histamine to suppress NE
overflow from sympathetic nerves (15). Therefore,
H3 agonists may offer a novel therapeutic approach to
myocardial ischemia, as suggested by Levi and Smith
(18). Whether this view is applicable to the ischemic kidney remains the subject of further study.
| |
ACKNOWLEDGEMENTS |
|---|
We thank M. Ohara for language assistance.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: Y. Matsumura, Dept. of Pharmacology, Osaka Univ. of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan (E-mail: matumrh{at}oysun01.oups.ac.jp).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 7 July 2000; accepted in final form 3 January 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Alves-Rodrigues, A,
Timmerman H,
Willems E,
Lemstra S,
Zuiderveld OP,
and
Leurs R.
Pharmacological characterization of the histamine H3 receptor in the rat hippocampus.
Brain Res
788:
179-186,
1998[Web of Science][Medline].
2.
Arrang, JM,
Garbarg M,
Lancelot JC,
Lecomte JM,
Pollard H,
Robba M,
Schunack W,
and
Schwartz JC.
Highly potent and selective ligands for histamine H3-receptors.
Nature
327:
117-123,
1987[Medline].
3.
Arrang, JM,
Garbarg M,
and
Schwartz JC.
Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor.
Nature
302:
832-837,
1983[Medline].
4.
Celuch, SM.
Possible participation of histamine H3 receptors in the modulation of noradrenaline release from rat spinal cord slices.
Eur J Pharmacol
287:
127-133,
1995[Web of Science][Medline].
5.
Clapham, J,
and
Kilpatrick GJ.
Histamine H3 receptors modulate the release of [3H]-acethylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes.
Br J Pharmacol
107:
919-923,
1992[Web of Science][Medline].
6.
Coruzzi, G,
Gambarelli E,
Bertaccini G,
and
Timmermann H.
Cardiovascular effects of selective agonists and antagonists of histamine H3 receptors in the anesthetized rat.
Naunyn-Schmiedeberg's Arch Pharmacol
351:
569-575,
1995[Web of Science][Medline].
7.
Egi, Y,
Matsumura Y,
Murata S,
Umekawa T,
Hisaki K,
Takaoka M,
and
Morimoto S.
The effects of NG-nitro-L-arginine, a nitric oxide synthase inhibitor, on norepinephrine overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs.
J Pharmacol Exp Ther
269:
529-535,
1994
8.
Endou, M,
Poli E,
and
Levi R.
Histamine H3-receptor signaling in the heart: possible involvement of Gi/Go proteins and N-type Ca++ channels.
J Pharmacol Exp Ther
269:
221-229,
1994
9.
Esler, M.
The sympathetic system and hypertension.
Am J Hypertens
13:
99S-105S,
2000[Web of Science][Medline].
10.
Godlewski, G,
Malinowska B,
Buczko W,
and
Schliker E.
Inhibitory H3 receptors on sympathetic nerves of the pithed rat: activation by endogenous histamine and operation in spontaneously hypertensive rats.
Naunyn-Schmiedeberg's Arch Pharmacol
355:
261-266,
1997[Web of Science][Medline].
11.
Hatta, E,
Yasuda K,
and
Levi R.
Activation of histamine H3 receptors inhibits carrier-mediated norepinephrine release in a human model of protracted myocardial ischemia.
J Pharmacol Exp Ther
283:
494-500,
1997
12.
Hayashi, K,
Matsumura Y,
Yoshida Y,
Suzuki Y,
and
Morimoto S.
The role of endogenous angiotensin II in antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs.
J Cardiovasc Pharmacol
17:
807-813,
1991[Web of Science][Medline].
13.
Hill, SJ,
Ganellin CR,
Timmerman H,
Schwartz JC,
Shankley NP,
Young JM,
Schunack W,
Levi R,
and
Hass HL.
International Union of Pharmacology. XIII. Classification of histamine receptors.
Pharmacol Rev
49:
253-278,
1997
14.
Hisa, H,
Araki S,
Tomura Y,
Hayashi Y,
and
Satoh S.
Effects of alpha adrenoceptor blockade on renal nerve stimulation-induced norepinephrine release and vasoconstriction in the dog kidney.
J Pharmacol Exp Ther
248:
752-757,
1989
15.
Imamura, M,
Poli E,
Abimbola T,
Omoniyi A,
and
Levi R.
Unmasking of activated histamine H3-receptors in myocardial ischemia: their role as regulators of exocytotic norepinephrine release.
J Pharmacol Exp Ther
271:
1259-1266,
1994
16.
Imamura, M,
Seyedi N,
Lander HM,
and
Levi R.
Functional identification of histamine H3-receptors in the human heart.
Circ Res
77:
206-210,
1995
17.
Ishikawa, S,
and
Sperelakis N.
A novel class (H3) of histamine receptors on perivascular nerve terminals.
Nature
327:
158-160,
1987[Medline].
18.
Levi, R,
and
Smith NCE
Histamine H3-receptors: a new frontier in myocardial ischemia.
J Pharmacol Exp Ther
292:
825-830,
2000
19.
Lovenberg, TW,
Roland BL,
Wilson SJ,
Jiang X,
Pyati J,
Huvar A,
Jackson MR,
and
Erlander MG.
Cloning and functional expression of the human histamine H3 receptor.
Mol Pharmacol
55:
1101-1107,
1999
20.
Malik, KU,
and
McGiff JC.
Modulation by prostaglandins of adrenergic transmission in the isolated perfused rabbit and rat kidney.
Circ Res
36:
599-609,
1975
21.
Matsumura, Y,
Matsuo G,
Egi Y,
Tadano K,
and
Morimoto S.
Inhibitory effect of endothelin-3 on antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs.
J Cardiovasc Pharmacol
28:
278-284,
1996[Web of Science][Medline].
22.
Matsuo, G,
Matsumura Y,
Tadano K,
and
Morimoto S.
Effects of sarafotoxin S6c on antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs.
J Pharmacol Exp Ther
280:
905-910,
1997
23.
Mazenot, C,
Ribout C,
Durand A,
Joulin Y,
Demenge P,
and
Godin-Ribout D.
In vivo demonstration of H3-histaminergic inhibition of cardiac sympathetic stimulation by R-
-methyl-histamine and its prodrug BP 2.94 in the dog.
Br J Pharmacol
126:
264-268,
1999[Web of Science][Medline].
24.
McLeod, RL,
Gertner SB,
and
Hey JA.
Species differences in the cardiovascular responses to histamine H3 receptor activation.
Eur J Pharmacol
259:
211-214,
1994[Web of Science][Medline].
25.
Molderings, GJ,
Weibenborn G,
Schlicker E,
Likungu J,
and
Göthert M.
Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein by presynaptic histamine H3-receptors.
Naunyn-Schmiedeberg's Arch Pharmacol
346:
46-50,
1992[Web of Science][Medline].
26.
Schlicker, E,
Behling A,
Lummen G,
Malinowska B,
and
Göthert M.
Mutual interaction of histamine H3-receptors and
2-adrenoceptors on noradrenergic terminals in mouse and rat brain cortex.
Naunyn-Schmiedeberg's Arch Pharmacol
345:
639-646,
1992[Web of Science][Medline].
27.
Schlicker, E,
Betz R,
and
Gothert M.
Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex.
Naunyn-Schmiedeberg's Arch Pharmacol
337:
588-590,
1988[Web of Science][Medline].
28.
Schlicker, E,
and
Marr I.
Mutual interaction of the presynaptic histamine H3 and prostaglandin EP3 receptors on the noradrenergic terminals in the mouse brain.
Neuroscience
79:
247-254,
1997[Web of Science][Medline].
29.
Starke, K,
Göthert M,
and
Kilbinger H.
Modulation of neurotransmitter release by presynaptic autoreceptors.
Physiol Rev
69:
864-989,
1989
30.
Suzuki, Y,
Matsumura Y,
Egi Y,
and
Morimoto S.
Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on norepinephrine overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs.
J Pharmacol Exp Ther
263:
956-963,
1992
31.
Suzuki, Y,
Matsumura Y,
Umekawa T,
Hayashi K,
Takaoka M,
and
Morimoto S.
Effects of endothelin-1 on antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs.
J Cardiovasc Pharmacol
19:
905-910,
1992[Web of Science][Medline].
32.
Tadano, K,
Yamasaki T,
and
Matsumura Y.
Inhibitory effects of proadrenomedullin N-terminal 20 peptide on antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs.
J Pharmacol Exp Ther
288:
522-528,
1999
33.
Vurek, GG,
and
Pegram SE.
Fluorometric method for the determination of nanogram quantities of inulin.
Anal Biochem
16:
409-419,
1966[Web of Science].
This article has been cited by other articles:
![]() |
V. Simonneaux and C. Ribelayga Generation of the Melatonin Endocrine Message in Mammals: A Review of the Complex Regulation of Melatonin Synthesis by Norepinephrine, Peptides, and Other Pineal Transmitters Pharmacol. Rev., June 1, 2003; 55(2): 325 - 395. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |